BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR) is a scientific society consisting of laboratory and clinical cancer researchers. It was founded in 1907 "to bring together active investigators of the cancer problem for presentation and discussion of new or significant observations; and to foster research in cancer and other phenomena of growth." Members of the AACR enjoy the following benefits:

1. a subscription to the journal Cancer Research at the reduced member rate;
2. the privilege of sponsoring an abstract for presentation at the AACR annual meeting;
3. an advance copy of the Program and Proceedings pertaining to each annual meeting;
4. a reduced registration rate at the annual meeting;
5. early notification of events in the AACR's new series of small scientific meetings;
6. subscriptions to any future AACR journals at reduced member rates;
7. preferred access to the AACR Employment Register;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas, and who have conducted two years of meritorious research that has resulted in publications relevant to cancer. If a candidate is working in a research area not directly related to the cancer field but has conducted research of exceptional scientific merit, he or she may also qualify for membership.

Corresponding membership is open to qualified persons who are not residents of the Americas. The requirements for corresponding membership are the same as those for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin soon after submitting their applications should apply for corresponding membership. All other individuals should apply for active membership and transfer to corresponding status at a later date if they should leave the Americas.

PROCEDURES FOR APPLICATION

There are two deadlines for receipt of a membership application: August 1 and December 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors, which formally elects all members. The same procedure is followed by the Special Memberships Committee, which receives applications for corresponding membership. Applicants who meet the August 1 deadline will be notified of the Board's decision in November, and, if elected, will be eligible to sponsor an abstract for the annual meeting of the AACR to be held the following Spring. Applicants meeting the December 1 deadline will be notified about their election in March.

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical standards.—OR—The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3. above from a secondor who is an active, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter).—OR—The secondor may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Temple University School of Medicine
West Building, Room 301
Broad and Tioga Streets
Philadelphia, PA 19140
215/221-4565

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues, a major portion of which is designated for a subscription to the AACR's official publication outlet, Cancer Research. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research at the higher, nonmember rate will receive reimbursement of the unused portion of that subscription once their first year's membership dues are paid in full. All corresponding members elected after May 23, 1985, are required to pay an annual assessment in lieu of dues. This assessment, which is equivalent to that portion of the regular dues that pertains to support of activities other than the journal Cancer Research, is imposed to defray the cost of sending AACR publications to members outside the Americas. Corresponding members may, if they wish, subscribe to Cancer Research at the reduced member rate.

Successful candidates will be expected to begin paying dues to the AACR in the year following receipt of their applications; e.g., successful applicants who meet either the August 1, or December 1, 1988 deadlines will begin to pay dues in 1989.

Margaret Foti
Executive Director
# Application for Membership

**Category of Membership:**
- [ ] Active
- [ ] Corresponding

**Name of Candidate:** __________________________  
**Present Position/Title:** __________________________  
**Date of Birth:** __________________________

**Institutional Affiliation:** __________________________  
**Institutional Address:** __________________________

**City**  
**State/Province**  
**Country**  
**Postal Code**  
**Telephone Number:** __________________________  
**Social Security Number:** __________________________

**Primary Field of Research** (Please check only one):
- [ ] Biochemistry and Biophysics  
- [ ] Biostatistics  
- [ ] Carcinogenesis  
- [ ] Cellular Biology and Genetics  
- [ ] Clinical Investigations  
- [ ] Endocrinology  
- [ ] Epidemiology  
- [ ] Immunology  
- [ ] Molecular Biology and Genetics  
- [ ] Preclinical Pharmacology and Experimental Therapeutics  
- [ ] Virology  
- [ ] Other: __________________________

**Academic Degrees** (Including where and when granted)

**Experience Since Highest Degree Was Granted** (Please list most recent first)

**Publications** (Reprints of two articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts.)

**Candidate Nominated By:** __________________________  
**Candidate Seconded By:** __________________________

**Statement of Support** (in place of letters of recommendation)

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

- How long has the candidate worked in the field of cancer research? ____ years  
- Will the candidate make a long-term contribution to cancer research? ____ Yes ____ No  
- Does the candidate's research adhere to accepted ethical standards? ____ Yes ____ No  
- I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator: __________________________  
Date: __________________________

Signature of seconder: __________________________  
Date: __________________________

See Guidelines for Application on the reverse side of this form for further instructions.

(This form may be reproduced.)
AMERICAN ASSOCIATION FOR CANCER RESEARCH
SEVENTY-NINTH ANNUAL MEETING
NEW ORLEANS CONVENTION CENTER, NEW ORLEANS, LOUISIANA
MAY 25-30, 1988

SCIENTIFIC SYMPOSIA
Wednesday, May 25: "Drug Resistance from the Molecular Level to Clinical Management"
Co-Chairmen: David A. Van Etten, University of Maryland Cancer Center, Baltimore, MD
Robert C. Young, National Cancer Institute, Bethesda, MD (sponsored jointly with the American Society of Clinical Oncology)

The widespread availability of drug-resistant human tumor cell lines and the techniques of molecular biology now allow rigorous investigation of the mechanisms of multidrug resistance. The identification of genes responsible for multidrug resistance, the genetic localization of growth regulatory sequences, and subcellular targets for drug injury have greatly increased our understanding of the problem and now suggest new clinical strategies to overcome drug resistance.

Michael M. Gutierrez, National Cancer Institute, Bethesda, MD
Jeffrey M. Trent, University of Arizona Cancer Center, Tucson, AZ
Leroy F. Liu, Johns Hopkins University School of Medicine, Baltimore, MD
Robert F. Ozoé, National Cancer Institute, Bethesda, MD
Robert L. Capco, Bowman Gray School of Medicine, Winston-Salem, NC

Thursday, May 26: "Approaches to the Prevention of Cancer"
Chairman: Emmanuel Farber, University of Toronto, Toronto, Canada

There are three possible approaches to the prevention of cancer development: (1) the removal or neutralization of the etiological agent(s), (2) the modulation of the metabolism so as to minimize the primary effects of carcinogens on target tissues, and (3) the manipulation of the long processes of tumour promotion and prevention of the slow cellular evolution from an early precursor lesion to cancer. Some of these approaches are to be discussed in some detail using cancer development in different particular organs as examples.

Emmanuel Farber
Lee W. Wattenberg, University of Minnesota, Minneapolis, MN
Jose Russo, Michigan Cancer Foundation, Detroit, MI
W. Robert Bruce, Ludwig Institute for Cancer Research, Toronto, Canada
Wallace H. Clark, Jr., University of Pennsylvania, Philadelphia, PA

Friday, May 27: "New Approaches to the Discovery of Anticancer Agents"
Chairman: Frederick A. Valentine, Wayne State University, Detroit, MI

During the past few years greater use of in vitro human cell lines, more emphasis on murine solid tumors, and the use of novel targets are producing striking new leads in drug development. Examples of each aspect of these changes will be presented together with information on chemotherapeutic agents which promise to lead to the next generation of cytotoxicities.

Thomas H. Corbett, Wayne State University, Detroit, MI
Warren E. Ross, University of Florida, Gainesville, FL
Nathan A. Berger, Case Western Reserve University, Cleveland, OH
Geoffrey R. Bailey, Lilly Research Laboratories, Indianapolis, IN
Robert C. Jackson, Warner-Lambert Company, Ann Arbor, MI
Terrance W. Doyle, Bristol-Myers Company, Wallingford, CT

Friday, May 27: "Growth Factors, Oncogenes, and the Control of Proliferation"
Chairman: W. Jackson Pledger, Vanderbilt University, Nashville, TN

Cellular and molecular biological research has provided new insights into the control of cellular proliferation, the development of neoplastic transformation, the regulation of proliferation by growth factors, and the relationship of growth factors and growth factor modulated cellular pathways to oncogenes and cancers. New and promising advances in these areas are reviewed, with a major emphasis on basic scientific rationale and clinical application.

Charles D. Stiles, Dana-Farber Cancer Center, Boston, MA
Harold L. Moses, Vanderbilt University, Nashville, TN
Dennis J. Simson, University of California, Los Angeles, CA

Friday, May 27: "Tumor Suppressor Genes — Mechanistic Aspects"
Chairman: Webster K. Cavenee, Ludwig Institute for Cancer Research, Montreal, Canada

Molecular biological analyses of cancer patients, their tumors, and their families have greatly increased our understanding of the chromosomal and genetic basis of human cancer. These investigations are also yielding novel conceptual and methodological approaches towards distinguishing between tumor subtypes and providing for accurate tests for prediction of tumor development. Each of these avenues of inquiry will be addressed with an emphasis on the genetic analysis of loci whose mutant forms predispose to disease.

Bernard E. Weissman, Children's Hospital of Los Angeles, Los Angeles, CA
Helmut Zatloukal, Massachusetts Institute of Technology, Cambridge, MA
John D. Minna, National Cancer Institute, Bethesda, MD

EMPLOYMENT REGISTER

Detailed listings of available positions and prospective candidates will be available for consultation during the annual meeting and will be published in the Proceedings and in two issues of the Association's journal Cancer Research. Interviews will be scheduled in New Orleans.

Fees

<table>
<thead>
<tr>
<th>Member Registration:</th>
<th>$65*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonmember Registration:</td>
<td>$110</td>
</tr>
<tr>
<td>Predoctoral Student Registration:</td>
<td>$35*</td>
</tr>
<tr>
<td>Proceedings of the AACR</td>
<td>$20</td>
</tr>
</tbody>
</table>

*10 Discount if received by April 29, 1988

Special Lectures

Thursday, May 25: Twenty-fifth C. H. Closest Memorial Award Lecture
"Clinical Factors in the Biology of Human Cancer Metastasis" — Dr. William D. Anderson, National Cancer Institute, Bethesda, MD

Tuesday, May 27: Leonard Pearl Memorial Lecture
"Metabolism of Acetylating Agents" — Dr. Herman A. Block, Youngstown, OH

Wednesday, May 28: Michael H. Heine Memorial Lecture
"Cytostatics and Drug Resistance: The Promising Future of Cancer Therapy" — Dr. David A. Van Etten, National Cancer Institute, Bethesda, MD

Scientific and Public Education Symposium

Scientific and Public Education Symposium

Wednesday, May 25: "The Status of Cancer Treatment: 1988"
Chairman: Harris Busch, Baylor College of Medicine, Houston, TX

Bruce A. Chabner, National Cancer Institute, Bethesda, MD
Emil Frei III, Dana-Farber Cancer Center, Boston, MA
Donald L. Morton, University of California, Los Angeles, CA
Alan Yagoda, Memorial Sloan-Kettering Cancer Center, New York, NY
Norbert Block, ASTA Pharma AG, Basel, Federal Republic of Germany

Presidential Address: "Immunomodulation by Anticancer Agents" — Enrico Mihch, Roswell Park Memorial Institute, Buffalo, NY

Methods Workshop

Saturday, May 28: "Cloning, Expressing, and Modifying Genes and Gene Products"
Chairman: Martin Rosenberg, Smith, Kline & French Laboratories, King of Prussia, PA

A presentation of state-of-the-art methods and techniques being used in gene cloning and expression, including new developments in protein engineering and the expression of gene products in a variety of recombinant systems. An additional registration fee of $10 will be required to cover incidental expenses. Advance registration strongly suggested.

Martin Rosenberg, University of California, Los Angeles, CA
Berk Bergsma, Smith, Kline & French Laboratories, King of Prussia, PA
Mitchell Reff, Smith, Kline & French Laboratories, King of Prussia, PA

Slide and Poster Sessions

Two thousand abstracts were received from scientists all over the world. Slide and poster sessions will be scheduled on all four days of the meeting in the fields of Biochemistry, Biology, Cancerogenesis, Clinical Investigations, Endocrinology, Epidemiology, Experimental Therapeutics, Immunology, Molecular Biology/Virology, and Preclinical Pharmacology.

MINISYMPOSIA and POSTER DISCUSSION SESSIONS

Special slide and poster formats providing stimulating overviews of certain timely areas in cancer research will be constructed from submitted abstracts and will be scheduled throughout the meeting.

The topics of the minisymposia are: immunosuppression by chemotherapeutic agents, breast cancer, biochemical modulation, signal transduction and protein kinase, eukaryotic and other membrane-active chemotherapeutic agents, mechanisms of tumor promotion, DNA adducts, cytokine action and cell cycle, and oncogenes and progression. The poster discussion sessions are devoted to invasion and metastasis, pediatric oncology, clinical pharmacology, cancerogen analogs with macromolecules, clinical and experimental studies of P-glycoprotein, virology, drug screening, nutrition and cancerogenesis, biochemical and molecular factors in drug resistance, and eosinophils and other lipid functions.

Networking for Young Investigators

The Program Committee has organized ten roundtable discussion groups during the lunch hour on Wednesday, May 25, for informal discussions between young investigators and prominent researchers. Participation will be on a first-come, first-served basis and will be limited to seven young investigators per roundtable. Sign-up sheets will be posted in the Registration Area as of noon on Tuesday, May 24.

Publications

The Proceedings of the American Association for Cancer Research contains all abstracts deemed acceptable by the Association's Program Committee and extended abstracts of special lectures. The Proceedings is available by all subscribers to the journal Cancer Research, or it may be purchased at the time of registration for $20.

The Joint Program of the American Association for Cancer Research and the American Society of Clinical Oncology is included in the registration fee.

Deadlines

Air Travel and Car Rental

McGraw-Hill Corporate Planning Services
834 Chestnut Street
Philadelphia, PA 19107-5104
March 29, 1988

American Association for Cancer Research
25-28, 1988

INFORMATION AND FORMS

American Association for Cancer Research
Temple University School of Medicine
West Building, Room 301
Philadelphia, PA 19140
215-221-4565
What will you tell her about screening mammography?

Many of your patients will hear about screening mammography through a program launched by the American Cancer Society and the American College of Radiology, and they may come to you with questions. What will you tell them?

We hope you’ll encourage them to have a screening mammogram, because that, along with your regular breast examinations and their monthly self examinations, offers the best chance of early detection of breast cancer, a disease which will strike one woman in 10.

If you have questions about breast cancer detection for asymptomatic women, please contact us.

<table>
<thead>
<tr>
<th>Age</th>
<th>Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>35-39</td>
<td>Baseline</td>
</tr>
<tr>
<td>40-49</td>
<td>Every 1-2 years</td>
</tr>
<tr>
<td>50 &amp; up</td>
<td>Every year</td>
</tr>
</tbody>
</table>

AMERICAN CANCER SOCIETY®

Professional Education Dept.
National Headquarters
90 Park Avenue
New York, New York 10016
or your local society

ACR
American College of Radiology
1891 Preston White Drive
Reston, Virginia 22091
(703) 648-8900